| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Iophenoxic acid binds to drug sites 1 and 2 on human serum albumin (HSA), with high-affinity binding occurring at drug site 1. This high-affinity binding to HSA contributes to its exceptionally long half-life in the body. It may also interact with various enzymes, proteins, and other biomolecules.
|
|---|---|
| ln Vitro |
In vitro, Iophenoxic acid is used in the direct quantitation of iophenoxic acid in porcine serum samples by liquid chromatographic-electrospray ionization mass spectrometry. Its structural basis of interaction with HSA has been evaluated. It enhances the contrast of X-ray images.
|
| ln Vivo |
In vivo, Iophenoxic acid was used as a radiocontrast agent for cholecystography. It has been used as a systemic blood marker for assessment of bait acceptance by stoats and weasels. Its exceptionally long half-life in the body led to its withdrawal from clinical use.
|
| Enzyme Assay |
Cell-free assays for Iophenoxic acid: HSA binding is assessed using fluorescence quenching or equilibrium dialysis. The compound is incubated with HSA and binding parameters are calculated. Radiocontrast properties are evaluated by X-ray attenuation measurements. Serum quantitation is performed using LC-MS/MS.
|
| Cell Assay |
Cellular assays for Iophenoxic acid: hepatocytes or other cell lines are treated with Iophenoxic acid at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. Cellular uptake and accumulation are assessed by ICP-MS or LC-MS/MS. Albumin binding is studied in cellular models expressing HSA.
|
| Animal Protocol |
In vivo animal studies for Iophenoxic acid: the compound is used in "bait acceptance" studies conducted on various animal species. Animals are administered Iophenoxic acid orally or by injection. Serum concentrations are measured by LC-MS/MS. Pharmacokinetic parameters and tissue distribution are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Iophenoxic acid: the compound has an exceptionally long half-life in the body due to its high-affinity binding to human serum albumin. This property led to its withdrawal from clinical use. It is an iodinated compound with poor elimination. Detailed PK parameters include extensive plasma protein binding and slow clearance.
|
| Toxicity/Toxicokinetics |
Toxicity of Iophenoxic acid: as an iodinated radiocontrast agent, it may have nephrotoxic potential. Its exceptionally long half-life raises concerns about cumulative toxicity. The compound was withdrawn from clinical use due to safety concerns. It is for research use only and not for human therapeutic use.
|
| References |
[1]. E. B. Spurr. Iophenoxic acid as a systemic blood marker for
|
| Additional Infomation |
Iodobenzoic acid belongs to the benzene family of compounds and is a monocarboxylic acid.
Iophenoxic acid is a research compound with applications in biomarker studies and wildlife research. It is also used as a reference standard for analytical applications. Its mechanism involves high-affinity binding to serum albumin. No clinical applications are currently approved. |
| Molecular Formula |
C11H11I3O3
|
|---|---|
| Molecular Weight |
571.92
|
| Exact Mass |
571.784
|
| CAS # |
96-84-4
|
| PubChem CID |
7315
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.471g/cm3
|
| Boiling Point |
459ºC at 760mmHg
|
| Melting Point |
146-148ºC(lit.)
|
| Flash Point |
231.4ºC
|
| Index of Refraction |
1.724
|
| LogP |
3.859
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(CC1=C(C(=C(C=C1I)I)O)I)C(=O)O
|
| InChi Key |
GOIQOQCNFWYSTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11I3O3/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5,15H,2-3H2,1H3,(H,16,17)
|
| Chemical Name |
2-[(3-hydroxy-2,4,6-triiodophenyl)methyl]butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7485 mL | 8.7425 mL | 17.4850 mL | |
| 5 mM | 0.3497 mL | 1.7485 mL | 3.4970 mL | |
| 10 mM | 0.1748 mL | 0.8742 mL | 1.7485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
